A Breakthrough In Ovarian Cancer

Researchers have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib, according to a paper in The Lancet Oncology which show that selumetinib targets a mutation in the MAPK pathway for patients with low-grade serous carcinoma, allowing for treatment on previously chemoresistant tumors. "This is a potentially important breakthrough for the Gynecologic Oncology Group," said first author John Farley, MD, a gynecologic oncologist at St. Joseph's Hospital.   read more

Read the whole article on

More from